Emil. J. Freireich

Emil. J. Freireich's AcademicInfluence.com Rankings

Emil. J. Freireich

Philosophy

#2706

World Rank

#4536

Historical Rank

Logic

#731

World Rank

#1251

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Emil. J. Freireich's Degrees

Masters Medicine University of Illinois College of Medicine

Why Is Emil. J. Freireich Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Emil. J. Freireich's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. (1966) (2329)
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. (1966) (1401)
Flow cytometry in clinical cancer research. (1983) (782)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. (1982) (744)
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. (2000) (715)
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. (2000) (702)
Rituximab dose-escalation trial in chronic lymphocytic leukemia. (2001) (629)
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia (2004) (525)
CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. (1965) (466)
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. (1998) (459)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System (2008) (457)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. (2016) (444)
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. (1987) (432)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. (2010) (328)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. (2003) (320)
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia (1989) (294)
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. (1987) (293)
The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy (1963) (290)
Characteristics of accelerated disease in chronic myelogenous leukemia (1988) (285)
CAUSES OF DEATH IN ADULTS WITH ACUTE LEUKEMIA (1976) (277)
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. (1986) (268)
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. (1982) (265)
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. (1993) (261)
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. (1965) (261)
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. (1988) (258)
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. (1991) (253)
Non-randomized controls in cancer clinical trials. (1974) (249)
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. (2006) (247)
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. (1971) (244)
Cells Capable of Colony Formation in the Peripheral Blood of Man (1971) (242)
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. (1989) (230)
Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. (1988) (228)
Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis (2003) (226)
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. (1974) (225)
Active immunotherapy with B.C.G. for recurrent malignant melanoma. (1973) (223)
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. (1985) (221)
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. (2006) (210)
Acute promyelocytic leukemia. M.D. Anderson Hospital experience. (1986) (209)
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. (1999) (206)
Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate (1961) (206)
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. (1994) (204)
Causes of initial remission induction failure in acute myelogenous leukemia. (1982) (199)
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. (2003) (197)
Response to salvage therapy and survival after relapse in acute myelogenous leukemia. (1989) (179)
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia (2008) (179)
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. (1974) (175)
Subarachnoid distribution of drugs after lumbar injection. (1962) (172)
Progress and perspectives in the chemotherapy of acute leukemia. (1965) (171)
Factors related to length of complete remission in adult acute leukemia (1980) (169)
THE FUNCTION AND FATE OF TRANSFUSED LEUKOCYTES FROM DONORS WITH CHRONIC MYELOCYTIC LEUKEMIA IN LEUKOPENIC RECIPIENTS (1964) (168)
Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. (1977) (168)
Separation and collection of leukocytes. (1965) (164)
Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. (1987) (159)
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. (1995) (157)
A comparative study of two regimens of combination chemotherapy in acute leukemia. (1958) (155)
Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. (1998) (154)
The incidence of central nervous system leukemia in adults with acute leukemia (1974) (152)
Twenty-five years of peripheral blood stem cell transplantation. (2011) (152)
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. (1974) (151)
Improved prospects for long-term survival in adults with acute myelogenous leukemia. (1982) (144)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Pulmonary complications of acute leukemia (1966) (139)
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). (1985) (136)
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. (1998) (136)
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. (2003) (134)
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. (1986) (133)
The effect of chemotherapy on acute leukemia in the human. (1961) (133)
Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. (1976) (133)
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. (2002) (131)
URIC ACID EXCRETION AND RENAL FUNCTION IN THE ACUTE HYPERURICEMIA OF LEUKEMIA. PATHOGENESIS AND THERAPY OF URIC ACID NEPHROPATHY. (1964) (131)
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. (1989) (129)
Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival (2001) (128)
RANDOMIZED TRIAL OF PROTECTED ENVIRONMENT — PROPHYLACTIC ANTIBIOTICS IN 145 ADULTS WITH ACUTE LEUKEMIA (1978) (125)
Myelodysplastic syndrome is not merely "preleukemia". (2002) (125)
THE PERSISTENCE OF EXTRAMEDULLARY LEUKEMIC INFILTRATES DURING BONE MARROW REMISSION OF ACUTE LEUKEMIA. (1965) (124)
Hepatotoxic effects of methotrexate (1966) (123)
A distinctive type of intracerebral hemorrhage associated with “blastic crisis” in patients with leukemia (1960) (121)
Eradication of minimal residual disease in hairy cell leukemia. (2006) (121)
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. (1988) (120)
Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine (1993) (119)
A four‐year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia (1981) (119)
Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. (1979) (118)
Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. (1969) (116)
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. (1973) (114)
Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia (1971) (114)
Prognostic significance of pretreatment proliferative activity in adult acute leukemia (1977) (113)
Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. (1980) (113)
Differences in CD33 intensity between various myeloid neoplasms. (2002) (111)
The natural history of resectable metastatic melanoma (Stage IVA Melanoma) (1982) (111)
The central nervous system in acute leukemia: a postmortem study of 117 consecutive cases, with particular reference to hemorrhages, leukemic infiltrations, and the syndrome of meningeal leukemia. (1960) (111)
A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia (1982) (110)
Prognostic factors in acute leukemia. (1976) (109)
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. (1999) (109)
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. (1970) (107)
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. (1993) (107)
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. (1999) (106)
Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types (1980) (106)
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. (1982) (104)
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. (1985) (103)
Reporting outcomes in Hodgkin's disease and lymphoma. (1987) (103)
A simplified in vitro classification for prognosis in adult acute leukemia: the application of in vitro results in remission-predictive models. (1976) (102)
The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. (1976) (102)
In vitro determination of thymidine-3H labeling index in human solid tumors. (1974) (101)
Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of Ph1 chromosome. (1970) (100)
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. (1987) (100)
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years (2008) (99)
Meningeal leukemia (1960) (99)
Impact of high‐dose granulocyte transfusions in patients with cancer with candidemia (2004) (98)
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil). (1976) (97)
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. (2007) (94)
Inhibition of the local inflammatory response in man by antimetabolites. (1966) (93)
Subacute pulmonary failure complicating therapy with high‐dose ara‐C in acute leukemia (1985) (93)
Complete remissions in metastatic breast cancer treated with combination drug therapy. (1979) (93)
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. (1980) (92)
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. (1997) (91)
Increased Granulocyte Collection with the Blood Cell Separator and the Addition of Etiocholanolone and Hydroxyethyl Starch (1974) (90)
Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. (1989) (90)
The Transfusion of Leukocytes from Donors with Chronic Myelocytic Leukemia to Patients with Leukopenia * (1966) (90)
Clinical implications of aneuploid cyto genetic profiles in adult acute leukemia (1974) (89)
Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia (1992) (89)
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer (1982) (89)
Therapy of acute myelogenous leukemia (1978) (88)
THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER (1981) (87)
Cytogenetic studies and their clinical correlates in adults with acute leukemia. (1971) (87)
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. (1995) (86)
LEUKOPENIA, BONE PAIN, AND BONE NECROSIS IN PATIENTS WITH ACUTE LEUKEMIA: A CLINICOPATHOLOGIC COMPLEX. (1965) (86)
The characteristics and outcome of patients with late relapse acute myelogenous leukemia. (1988) (85)
High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. (1986) (84)
The relevance of reticulin stain‐measured fibrosis at diagnosis in chronic myelogenous leukemia (1987) (84)
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (2007) (84)
The nature and control of infections in patients with acute leukemia. (1965) (83)
The association of fatal intracranial hemorrhage and blastic crisis in patients with acute leukemia. (1959) (83)
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. (2001) (82)
BCR rearrangement-negative chronic myelogenous leukemia revisited. (2001) (82)
Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. (1974) (79)
Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response. (1974) (79)
Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count (1983) (78)
Effectiveness of Platelet Transfusion in Leukemia and Aplastic Anemia (1966) (78)
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection (1995) (77)
MULTIPLE ORGANISM SEPTICEMIA IN ACUTE LEUKEMIA; ANALYSIS OF 54 EPISODES. (1965) (77)
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. (1976) (77)
Protection against chemotherapy toxicity by IV hyperalimentation. (1978) (76)
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. (1989) (75)
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (75)
Late intensification therapy for acute leukemia in remission. Chemotherapy and immunotherapy. (1976) (74)
Studies of a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results (1968) (74)
Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. (1984) (72)
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution (2009) (72)
Phenotypic and molecular heterogeneity in Philadelphia chromosome-positive acute leukemia. (1988) (71)
Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. (1988) (71)
CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA (1975) (71)
Persistent Mitosis of Transfused Homologous Leukocytes in Children Receiving Antileukemic Therapy (1963) (71)
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. (1990) (70)
Studies of patients in a laminar air flow unit (1969) (70)
Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP) (1981) (69)
FOLIC ACID ANTAGONIST. EFFECTS ON THE CELL AND THE PATIENT. COMBINED CLINICAL STAFF CONFERENCE AT THE NATIONAL INSTITUTES OF HEALTH. (1963) (69)
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies (2013) (68)
Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer (1978) (68)
Progress in the treatment of adults with acute leukemia: review of regimens containing cytarabine studied by the Southwest Oncology Group. (1976) (68)
Inhibition of the primary immune response in man by anti-metabolites. (1965) (67)
Role of maintenance chemotherapy in acute promyelocytic leukemia (1987) (67)
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s (1985) (66)
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. (1983) (66)
Effect of Storage up to 48 Hours on Response to Transfusions of Platelet Rich Plasma (1964) (66)
Animal toxicology for early clinical trials with anticancer agents. (1981) (66)
A PRELIMINARY REPORT ON VINCRISTINE SULFATE—A NEW ACTIVE AGENT FOR THE TREATMENT OF ACUTE LEUKEMIA (1962) (65)
Phase II trial of mitoxantrone in refractory acute leukemia. (1983) (65)
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide. (1974) (64)
Leukocyte transfusion therapy for patients with host-defense failure. (1973) (64)
Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. (2000) (64)
Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. (1989) (63)
Clinical trials of hydroxyurea in patients with cancer and leukemia (1964) (63)
Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase (2003) (62)
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. (1994) (62)
The importance of cytogenetic studies in adult acute lymphocytic leukemia. (1990) (62)
ATM gene deletion in patients with adult acute lymphoblastic leukemia (2000) (61)
Clinical and prognostic features of philadelphia chromosome‐negative chronic myelogenous leukemia (1986) (61)
The role of vincristine in the treatment of childhood acute leukemia (1966) (61)
Principles of blood separation and component extraction in a disposable continuous-flow single-stage channel (1979) (60)
Treatment of acute leukemia with 5-azacytidine (NSC-102816). (1973) (60)
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. (1995) (60)
Lethal activity of camptothecin sodium on human lymphoma cells. (1974) (60)
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. (1992) (59)
Complement‐Fixing Platelet Iso‐Antibodies in Serum of Transfused Persons. Correlation of Antibodies with Platelet Survival in Thrombocytopenic Patients (1964) (59)
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. (1972) (58)
Nodular malignant lymphomas. Factors affecting complete response rate and survival (1979) (58)
Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. (1985) (57)
A pilot study of interleukin‐2 for adult patients with acute myelogenous leukemia in first complete remission (1999) (57)
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. (1990) (57)
Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. (1997) (57)
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome (2010) (57)
Leukapheresis therapy of chronic lymphocytic leukemia. (1972) (57)
Meningeal leukemia. A follow‐up study (1965) (56)
The leukemias: a half-century of discovery. (2014) (56)
Blastic crisis in chronic granulocytic leukemia: Experience in 39 patients (1974) (54)
Mitoxantrone and high‐dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia (1990) (54)
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. (1990) (54)
Biological effects of repeated leukapheresis of patients with chronic myelogenous leukemia. (1973) (54)
Electron microscopic studies of human leukemia and lymphoma (1967) (54)
Clinical and prognostic features of patients with philadelphia chromosome‐positive chronic myelogenous leukemia and extramedullary disease (1987) (54)
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. (2004) (53)
Intensive chemotherapy induction followed by interferon‐alpha maintenance in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia (1991) (53)
Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia (1989) (53)
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. (1994) (53)
Pretreatment flow cytometry of DNA content in adult acute leukemia. (1980) (52)
Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia. (1962) (51)
Role of murine tumor models in cancer treatment research. (1986) (51)
Mitoxantrone and high‐dose cytosine arabinoside in refractory acute myelogenous leukemia (1988) (51)
In vitro growth of myeloid colonies from bone marrow of patients with acute leukemia in remission. (1970) (50)
Specific expression of the annexin VIII gene in acute promyelocytic leukemia. (1992) (50)
Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. (1978) (50)
Reduction of ifosfamide toxicity using dose fractionation. (1976) (49)
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. (1979) (48)
Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. (1984) (48)
Infection prophylaxis in acute leukemia (1984) (48)
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia (1988) (48)
Lymphocyte blastogenesis to human leukemia cells and their relationship to serum factors, immunocompetence, and prognosis. (1972) (47)
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. (1998) (46)
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? (2006) (46)
Therapy for acute granulocytic leukemia. (1967) (46)
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia (1990) (46)
Pulse cytophotometric analysis of cell cycle perturbation with bleomycin in vitro. (1976) (45)
Cytogenetic studies in 45 patients with acute lymphocytic leukemia. (1969) (45)
The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients (2008) (45)
Sudden onset of the blastic phase of chronic myelogenous leukemia (2003) (45)
A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. (1986) (45)
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside (1988) (45)
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. (1999) (45)
Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. (1981) (43)
Intensive treatment of acute leukemia in adults 70 years of age and older (1987) (43)
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome (2000) (42)
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (1988) (41)
Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia. (1993) (41)
A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. (1959) (41)
Serial labeling index determination as a predictor of response in human solid tumors. (1975) (41)
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. (1987) (41)
Subarachnoid Distribution of Drugs After Lumbar Injection. (1963) (40)
RECENT ADVANCES IN ACUTE LEUKEMIA. (1964) (40)
Leukemia and lymphoma. (1971) (40)
A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. (1985) (39)
Molecular heterogeneity in acute leukemia lineage switch. (1989) (39)
Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. (1979) (39)
Intrathecal aminopterin therapy of meningeal leukemia. (1963) (38)
A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. (1987) (38)
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. (1988) (38)
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS (2012) (38)
Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). (1981) (37)
Clinical Studies of 6-Azauracil (1960) (37)
Molecular heterogeneity in acute leukemia lineage switch (1989) (37)
Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients (1991) (37)
High‐dose chemotherapy with autologous bone marrow transplantation (1984) (36)
Principles of blood separation and component extraction in a disposable continuous-flow single-stage channel. (2000) (36)
Phase I study of maytansine using a 3-day schedule. (1978) (35)
Heterogeneity in acute undifferentiated leukemia. (1988) (35)
Prediction of Prognosis Following Fludarabine Used as Secondary Therapy for Chronic Lymphocytic Leukemia (2000) (35)
Angiogenesis and leukemia. (2001) (34)
Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. (1990) (34)
Correlations of the biochemical and clinical effects of 6-azauridine in patients with leukemia (1962) (34)
Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high‐dose decadron (1987) (33)
Repeated Leukapheresis of Patients with Chronic Myelocytic Leukemia (1966) (33)
A phase 1 and 2 trial of rubidazone in patients with acute leukemia. (1977) (33)
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. (2011) (33)
The role of investigational therapy in management of patients with advanced metastatic malignancy. (2009) (33)
Case report: tetraploid leukemia. (1971) (33)
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin. (1978) (32)
Chemoimmunotherapy of adult acute leukemia (1981) (32)
Cancer Clinical Trials: Methods and Practice (1985) (32)
Developmental therapy in adult acute leukemia. (1976) (32)
Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine. (2002) (31)
Toward the potential cure of leukemias in the next decade (2018) (31)
Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders. (1981) (30)
Response to Transfusion of Platelets Pooled from Multiple Donors and the Effects of Various Technics of Concentrating Platelets (1965) (30)
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. (1998) (29)
DNA aneuploidy in adult acute leukemia. (1987) (29)
Exchange of inulin and dextran between blood and cerebrospinal fluid. (1961) (29)
Long‐term second remissions in acute lymphatic leukemia (1975) (29)
Hypersplenism due to disseminated candidiasis in a patient with acute leukemia (1969) (28)
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia (1989) (28)
Phase I clinical studies with gallium nitrate. (1978) (28)
Therapy of adult acute leukemia with daunorubicin and L‐asparaginase (1974) (28)
Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. (2000) (27)
Modulation of 9-β-d-Arabinofuranosyladenine 5′-Triphosphate and Deoxyadenosine Triphosphate in Leukemic Cells by 2′-Deoxycoformycin during Therapy with 9-β-d-Arabinofuranosyladenine (1982) (27)
Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. (2003) (27)
Charles F. Kettering prize. Acute leukemia. A prototype of disseminated cancer (1984) (27)
Familial myeloid leukemia associated with loss of the long arm of chromosome 5. (1996) (27)
Origins of platelet transfusion therapy. (2011) (26)
Inhibition of in vitro lymphocyte blastogenesis by inhibitor produced by cultured human lymphoblasts. (1974) (26)
Supportive care for patients with blood disorders. (2000) (26)
Prolonged remissions in adults with acute leukemia following late intensification chemotherapy and immunotherapy (1981) (26)
Phase I clinical evaluation of anguidine. (1978) (26)
Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy. (1983) (26)
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. (1996) (25)
Arabinosyl cytosine: a 20-year update. (1987) (25)
Disseminated histiocytosis associated with atypical lymphoid cells (lymphohistiocytosis) (1966) (24)
Some studies on natural killer cells in man. (1979) (24)
Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. (1981) (24)
Platelet and leukocyte transfusions in acute leukemia. (1974) (24)
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. (1992) (24)
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia (2002) (23)
Terminal Deoxynucleotidyl Transferase Expression in Acute Myelogenous Leukemia and Myelodysplasia as Determined by Flow Cytometry (2000) (23)
Immunodiagnosis of acute leukemia: detection of residual disease. (1974) (23)
Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy (1985) (23)
Standardization of platelet function tests (1981) (23)
Pneumonia during remission induction chemotherapy in patients with AML or MDS. (1996) (22)
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia (2013) (22)
Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia. (1988) (22)
Clinical and morphological correlations in acute promyelocytic leukemia. (1975) (22)
Host defense, chemical immunosuppression, and the transplant recipient. Relative effects of intermittent versus continuous immunosuppressive therapy with reference to the objectives of treatment. (1973) (22)
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. (1987) (21)
Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. (1979) (21)
Initial clinical studies with bruceantin. (1979) (21)
Joining of recombination signals on the der 14q- chromosome in T-cell acute leukemia with t(10;14) chromosome translocation. (1994) (21)
Mononuclear cell (MNC) collection by continuous‐flow centrifugation (CFC) (1983) (21)
Remission Induction in Adults with Acute Myelogenous Leukemia (1970) (21)
Treatment of acute leukemia in protected environment units (1979) (21)
Peripheral acute leukemia: high peripheral but low-marrow blast count. (1989) (20)
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. (1987) (20)
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines (2003) (20)
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 (2018) (20)
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome (2006) (20)
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. (2005) (20)
Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia. (1988) (19)
Natural Killer Cells in Man: Their Possible Involvement in Leukemia and Bone Marrow Transplantation (1979) (19)
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon‐α (2000) (19)
Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q (2000) (19)
Expression of differentially phosphorylated Rb and mutant p53 proteins in myeloid leukemia cell lines. (1993) (19)
Remission from central nervous system involvement in adults with acute leukemia effect of intensive therapy and prognostic factors (1985) (19)
Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. (2008) (19)
Evaluation of a new chemotherapeutic agent in patients with 'advanced refractory' acute leukemia. Studies of 6-azauracil. (1960) (19)
Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives. (1979) (19)
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. (1999) (18)
Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA). (1980) (18)
Old Age: A Sign of Poor Prognosis in Patients With Chronic Myelogenous Leukemia (1987) (18)
Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. (1980) (18)
Primary and Secondary Immune Responses in the Evaluation of Immunocompetence and Prognosis in Cancer Patients (1974) (18)
Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer. (1968) (18)
Combination 6‐mercaptopurine‐adriamycin in refractory adult acute leukemia (1975) (18)
Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials. (1982) (17)
Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells. (1980) (17)
Cell-mediated and humoral immune response to acute leukemia cells and soluble leukemia antigen--relationship to immunocompetence and prognosis. (1973) (17)
Effect of splenectomy on the response to platelet transfusion in three patients with aplastic anemia. (1966) (17)
Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. (1985) (17)
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. (1985) (17)
THE EFFECT OF ADRENAL CORTICOSTEROID THERAPY ON INFECTIONS IN ACUTE LEUKEMIA (1965) (17)
Molecular Basis of Oncology (1995) (16)
The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. (1999) (16)
White cell transfusions born again. (1993) (16)
Cancer clinical trials. A rational basis for use of historical controls. (1981) (16)
Antigen-specific immunity in recipients of leukocyte transfusions from immune donors. (1970) (16)
Kinetic response of human lymphoid cells to adriamycin-DNA complex in vitro. (1976) (16)
MECHANISM OF PRODUCTION OF INHIBITOR OF LYMPHOCYTE BLASTOGENIC RESPONSE TO MITOGENS BY CULTURED LYMPHOBLASTOID CELL LINE CELLS (1974) (16)
Management of adult acute leukemia a southwest oncology group study (1983) (16)
Erythroid homograft following leukocyte transfusion in a patient with acute leukemia. I. Clinical studies and implications. (1965) (16)
Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system (1977) (16)
Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. (2000) (16)
Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. (1979) (15)
The history of leukemia therapy--a personal journey. (2012) (15)
Early consolidation chemotherapy for adults with acute leukemia in remission. (1976) (15)
Milestones in leukemia research and therapy (1991) (15)
Different patterns of remission in acute myelocytic leukemia. A comparison of the effects of methyl-glyoxal-bis-guanylhydrazone and 6-mercaptopurine. (1963) (15)
Deletions in the 13q14 locus in adult lymphoblastic leukemia (2000) (15)
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. (1984) (15)
Comparison of results of salvage therapy in adult acute myelogenous leukemia. (1987) (15)
Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients (1982) (15)
Who took the clinical out of clinical research?--Mouse versus man: seventh David A Karnofsky Memorial Lecture--1976. (1997) (15)
Clinical pharmacology of O2,2'‐cyclocytidine (1975) (14)
Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. (1991) (14)
Initial clinical studies of vindesine. (1981) (14)
DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy. (1985) (14)
The myeloperoxidase gene is translocated from chromosome 17 to 15 in a patient with acute promyelocytic leukemia. (1988) (14)
Leukemia: Advances in Research and Treatment (1993) (14)
Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2. (1987) (14)
Radioimmunoassay for the detection and quantitation of bruceantin. (1980) (13)
Four decades of therapy for AML. (1998) (13)
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (1997) (13)
MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells (2010) (13)
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. (1992) (13)
Phase I study of aziridinylbenzoquinone (NSC 182986). (1981) (13)
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. (1987) (13)
Treatment of meningeal leukemia with intrathecal aminopterin. (1962) (13)
Studies with ifosfamide in patients with malignant lymphoma. (1982) (12)
Platelet replacement therapy: a clinical assessment. (1978) (12)
Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). (1970) (12)
Effect of Platelets Stored at 22° C for 24 Hours in Patients With Acute Leukemia (1973) (12)
Acute leukemia. A prototype of disseminated cancer. (1984) (12)
Cell kinetics and the management of malignant disease (1981) (12)
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. (1999) (12)
Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate) (1976) (12)
Phase 2 study with Baker's Antifol in solid tumors. (1977) (12)
A study of the status of clinical cancer research in the United States (1990). (1991) (12)
Broad phase II study of vindesine. (1981) (11)
Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies. (1988) (11)
Glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. (1978) (11)
The road to the cure of acute lymphoblastic leukemia: a personal perspective. (1997) (11)
The clinical cancer researcher--still an embattled species. (1993) (11)
Clinical Pharmacology of Tetrahydrouridine (1978) (11)
Phase I evaluation of intravenous difluoromethylornithine — a polyamine inhibitor (2004) (11)
Should terminally ill patients have the right to take drugs that pass phase I testing? Yes (2007) (11)
Should the patient know? (1979) (10)
Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications. (1985) (10)
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. (1987) (10)
Schedule-dependent synergistic cytotoxicity of arabinofuranosylcytosine with adriamycin or 3,6-bis(5-chloro-2-piperidinyl)-2,5-piperazinedione in cultured cells. (1975) (10)
Recombinant human retinoblastoma protein inhibits cancer cell growth. (1995) (10)
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. (1999) (10)
Intermittent guanazole therapy in adult acute leukemia (1973) (10)
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. (2003) (10)
Clinical pharmacology of IMPY by radioimmunoassay. (1980) (10)
New prognostic factors affecting response and survival in adult acute leukemia (1974) (10)
Complement activation in vivo in cancer patients receiving C. parvum immunotherapy. (1976) (10)
Developmental and differential regulation of human MPO gene in leukemic cells. (1990) (9)
Prospective randomized trial of antibiotic prophylaxis in acute leukemia. (1985) (9)
Editorial: Historical controls reincarnated: an examination of techniques for clinical therapeutic research. (1974) (9)
Previous radiation exposure in patients with leukemia. (1973) (9)
Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors (2004) (9)
Effect of schedule and combinations on clinical effectiveness of Ara-C in adult acute leukemia. (1982) (9)
A phase I study of pyrazofurin (1977) (9)
Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal. (2006) (9)
Frequency of HLA antigens in chronic myelocytic leukemia. (1977) (9)
Tongue worm (Linguatula serrata) infestation in a patient with acute leukemia. (1957) (9)
Molecular Defects in Chronic Myeloproliferative Disorders (2000) (9)
Phase I--II study of 3-deazauridine in adults with acute leukemia. (1981) (9)
PLATELET THERAPY AND RED CELL DEFECT IN APLASTIC ANEMIA. (1964) (9)
Combinations of arabinosyl cytosine and 6-thioguanine for treatment of adults with acute leukemia. (1975) (9)
Continuous‐flow techniques for platelet concentrate collection: A step toward standardization and yield predictability (1985) (8)
Control of Alimentary Symptoms in Far Advanced Cancer (1987) (8)
The 6-MP versus placebo clinical trial in acute leukemia (2011) (8)
Augmentation of adriamycin's therapeutic index by prolonged continuous i.v. infusion for advanced breast cancer (1979) (8)
Vindesine in the Therapy of Solid Tumors (1981) (8)
5-AZACYTIDINE AND ARABINOSYL ADENINE FOR THE TREATMENT OF ACUTE LEUKEMIA* (1977) (8)
Granulocyte transfusions: from neutrophil replacement to immunereconstitution. (2000) (8)
Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. (1978) (8)
Prognostic factors for survival of 194 patients with low infiltrate leukemia. (1986) (8)
Increased remission rate and prolongation of survival in patients with soft tissue sarcomas treated with intensive chemotherapy on a protected environment prophylactic antibiotic program (PEPA) (1977) (8)
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. (1996) (8)
Editorial: Focus on cutaneous host-defense failure in transplant recipients. (1974) (8)
Current Status of Therapy for Acute Leukemia (1971) (8)
Human immune response to active immunization with Rauscher leukemia virus. I. Cell-mediated and cell-associated immunity. (1974) (7)
Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. (1996) (7)
The hematologic malignancies: Leukemia, lymphoma, and myeloma (1984) (7)
Evolution of oligoleukemia (1984) (7)
Min Chiu Li: a perspective in cancer therapy. (2002) (7)
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation? (2000) (7)
Clinical Pharmacology of Arabinosylcytosine (1975) (7)
Comparison of Uptake and Intracellular Induced Structural Changes of Arsenic Trioxide, an Inorganic Compound, and Organic Arsenic Derivative S-Dimethylarsino-Glutathione (SGLU; ZIO-101) in NB4 Acute Promyelocytic Leukemia (APL) Cells. (2005) (7)
Leukocyte transfusion and the development of the continuous-flow blood cell separator. (2011) (7)
T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity. (1987) (7)
Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity (2003) (7)
Factors influencing patient selection for chemotherapy studies of acute leukemia. (1962) (7)
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation (2004) (6)
p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro. (1995) (6)
Protected Environment, Prophylactic Antibiotics and Cancer Chemotherapy (1970) (6)
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells. (2012) (6)
A study of intermittent alternating drug program reinduction therapy on the frequency and duration of response in adult acute leukemia. (1976) (6)
Prolonged survival of a leukemic patient in a protected environment. (1968) (6)
Combination chemotherapy for lymphomas and leukemias. (1973) (6)
Interferon α therapy for patients with essential thrombocythemia (2005) (6)
Ethical considerations in cancer chemotherapy. (1979) (6)
The investigational new drug application—who benefits? (2006) (6)
Blood components in the care of the cancer patient (1978) (6)
Landmark perspective: Nitrogen mustard therapy. (1984) (6)
Training in clinical research in oncology. (1991) (6)
Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant Chronic (6)
Principles of Continuous Flow Cell Separation in a Circumferential Flow Disposable Channel (1980) (5)
AN OVERVIEW OF CANCER: Molecular, Genetic, and Immunologic Concerns for Anesthesia (1998) (5)
Treatment of malignancies, past and present. (1993) (5)
PHARMACOLOGICAL AND CLINICAL STUDIES OF SOME NUCLEOSIDE ANALOGS * (1975) (5)
Prognostic factors in hairy cell leukemia. (Leukemic reticuloendotheliosis) (1984) (5)
The Use of Hematopoietic Growth Factors for Recruitment of Leukocytes for Transfusion (1999) (5)
Combination chemotherapy in vitro. III. BCNU. (1979) (5)
FLAG-Ida, an Effective Regimen for High Risk AML (1998) (5)
The future of clinical cancer research in the next millennium. (1997) (5)
Grounds for Optimism in Treating Acute Granulocytic Leukemia (Adult Acute Leukemia): A Look at the Data (1976) (5)
The Impact of Cytogenetics and Molecular Genetics on Diagnosis and Treatment (1990) (5)
Development of an organic arsenic derivative as a therapy for leukaemia (2003) (5)
Bacterial and fungal infections during cancer chemotherapy (1974) (5)
Hairy cell leukemia with large cells: long disease course with adequate response to therapy (2004) (5)
Methods for evaluating response to treatment in adult acute leukemia. (1983) (5)
Can we conquer cancer in the twenty-first century? (2001) (5)
Organic Arsenic Lipid Derivatives Are More Potent and Less Toxic Than Inorganic Arsenic Trioxide in Preclinical Testing. (2004) (4)
Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation. (2012) (4)
CI-973, a new platinum derivative with potential antileukemic activity. (1992) (4)
Therapy of hematopoietic neoplasia (1991) (4)
A controlled clinical trial to evaluate a protected environment and prophylactic antibiotic program in the treatment of adult acute leukemia. (1975) (4)
Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. (2000) (4)
Importance of Bulk Flow in the Exchange of Compounds across the Blood Cerebrospinal Fluid Barrier (1962) (4)
Chemoimmunotherapy of adult acute leukemia (CIAL) (1977) (4)
Neutropenia and infection following cancer chemotherapy. (1976) (4)
Nitrogen Mustard Therapy (1984) (4)
Biotransformation of ftorafur (FT, NSC 148958) in man (1977) (4)
Molecular Genetics and Therapy of Leukemia (1996) (4)
Clinica, pharmacology of tetrahydrouridine. (1978) (4)
Acute leukemia in adults, 1977 (1977) (4)
Biologic and Treatment Determinants of Curability in Acute Myelogenous Leukemia (1986) (4)
A method for evaluation of novel therapy in previously untreated patients: AMSA-OAP combination therapy in adult acute leukemia (1982) (4)
Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. (1982) (4)
In Vitro Evaluation of 1-β-D-Arabinofuranosylcytosine-β-2-Deoxythioguanosine Combination Chemotherapy (1974) (4)
The influence of a new analgetic-antiphlogistic compound (2-(2-methyl-3'chloro)-anilino-nicotinic acid) on platelet function and fibrinolytic activity in vitro. (1975) (3)
Phase II study of EL625, a p53 antisense oligonucleotide, and chemotherapy in refractory and relapsed acute myelogenous leukemia (AML) (2005) (3)
Supportive therapy in acute leukemia (1964) (3)
Randomization in Phase II Clinical Trials. (2006) (3)
Dose-response relationship in experimental and clinical oncology. (1984) (3)
The Transformed Cell: Unlocking the Mysteries of Cancer (1993) (3)
438 POSTER Organic and inorganic arsenics operate by different biochemical pathways to induce apoptosis in cancer cells (2006) (3)
Histocompatibility antigens in adult acute leukemia. (1977) (3)
Cellular pharmacology of arabinosylcytosine 5'-triphosphate (araCTP) in leukemic cells during high-dose araC therapy (1982) (3)
Replacement transfusion therapy of thrombocytopenia and leukopenia. (1964) (3)
LYMPHOMA-ASSOCIATED AND HL-A ANTIGENS IN THE MIXED LEUKOCYTE REACTIVITY BETWEEN IDENTICAL SIBLINGS (1973) (3)
The management of acute leukemia. (1967) (3)
Cytogenetic Features of Hodgkin's Disease Suggest Possible Origin (2011) (3)
Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. (1990) (3)
Advances in the chemotherapy of acute leukemia. (1970) (3)
Short-term sequential (S-TS) chemotherapy in young patients with acute myelogenous leukemia (AML) (1981) (3)
Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience (2016) (2)
Treatment of adult acute myeloblastic leukemia. (1979) (2)
Enrichment of oncolytic cells for adoptive therapy using centrifugal elutriation. (1990) (2)
Granulocyte concentrates from a single high-yield apheresis can be split to support multiple patients (2012) (2)
Cross cellular contamination in plateletpheresis, leukapheresis and plasma exchange. (1981) (2)
Sequential administration of thymidine, 5‐fluorouracil, and PALA: A phase I‐II study (1985) (2)
Editorial: Progress in the treatment of colorectal cancer. (1976) (2)
Medical management of hematological malignant diseases (1998) (2)
Investigations in acute leukemia. (1960) (2)
2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies (1991) (2)
Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic study. (1987) (2)
Is there any mileage left in the randomized clinical trial? (1990) (2)
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia. (1987) (2)
Is cancer prevention better than cure? (1979) (2)
The african organization for research and training in cancer. (2012) (2)
Can we afford to treat acute leukemia? (1980) (2)
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. (1985) (2)
BCR Rearrangement-Ne gative C hronic M yelogenous Leukemia R evisited (2001) (2)
New progressive factors affecting response and survival in adult acute leukemia. (1974) (2)
Chemotherapy alone for management of stage I and II malignant lymphoma of unfavorable histology (1979) (2)
Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation. (2005) (2)
Mechanisms of increased reactive oxygen species (ROS) generation induced by organic arsenic derivative S-dimethylarsino-glutathione (SGLU ; ZIO-101). (2005) (2)
Clinical and pharmacological studies of the folate antagonist, triazinate (Baker's antifol, TZT) (1974) (2)
Doxorubicin-DNA complex: a phase I clinical trial. (1982) (2)
Ethical considerations in clinical trials: invited remarks. (1979) (2)
Research contributions to combination chemotherapy. (1972) (1)
Levamisole induced decline in lymphocyte content of cAMP among patients with solid tumors (1977) (1)
New strategies in the management of acute leukemias. (1987) (1)
Clinical sequence relationship between vinblastine and doxorubicin (1982) (1)
Detection of the AML 1 / ETO Fusion Transcript in the t ( 8 ; 21 ) Masked Translocation in Acute Myelogenous Leukemia I (2007) (1)
Knowledge acquisition from historical data: application to breast cancer patients. (1980) (1)
Protected environments (PE) and prophylactic antibiotics in remission induction therapy of adults with acute leukemia (1974) (1)
Principles of blood separation and component extraction in a disposable continuous-flow single-stage channel. 1979. (2000) (1)
“T-Cell-Rich B-Cell Lymphoproliferative Disorder” of the Bone Marrow (2001) (1)
Depletion of patients' plasma tryptophan using tryptophan side-chain oxidase columns. (1993) (1)
A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients. (2006) (1)
The contribution of gnotobiology to the treatment of neoplasia: Clinical aspects (1979) (1)
A clinical trial of sarcolysin in acute leukemia. (1961) (1)
Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis (1979) (1)
Prognotic significance of pretreatment proliferative activity in adult acute leukemia. (1977) (1)
Hematologic malignancies: adult acute leukemia. (1986) (1)
The road to cancer control goes through leukemia research (2009) (1)
Symposium on vindesine. Chairman's introductory remarks. (1980) (1)
Ethidium bromide (EB) and mithramycin (MI) for DNA histograms of hemopoietic cells (1976) (1)
Phase 1 study of anti-CD 33 immunotoxin HUM-195 / rGEL in patients with advanced myeloid malignancies (2012) (1)
Death with dignity (1974) (1)
Chairman's introductory remarks (1980) (1)
In vitro evaluation of 1-beta-D-arabinofuranosylcytosine-beta-2'-deoxythioguanosine combination chemotherapy. (1974) (1)
Myron r. karon--a tribute. (1975) (1)
Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients. (2006) (1)
Impact of cytogenetics and molecular genetics on leukemia therapy. (1992) (1)
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. (1968) (1)
Progress in the Treatment of Colorectal Cancer (1976) (1)
Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration (1988) (1)
Laminar air flow rooms: use for patients with leukemia. (1972) (1)
Granulocyte transfusion: an overview. (1981) (1)
Pharmacokinetic Simulation: A Future Means for Better Control of Cancer Chemotherapy (1974) (1)
Polyamines increase in human peripheral blood and bone marrow mononuclear cells following administration of methylglyoxal bis(guanylhydrazone). (1988) (1)
Ethical issues in clinical trials. (1988) (1)
Current status of the treatment of disseminated disease. (1984) (1)
Effect of platelets stored at 22 degrees C for 24 hours in patients with acute leukemia. (1973) (1)
Hematological abnormalities of disseminated cancer. (1976) (1)
History of acute leukemia (2013) (0)
Acute lymphatic leukemia (1973) (0)
Message from the Chairmen. (2020) (0)
Late intensification (LI) chemoimmunotherapy in adult acute leukemia (AL) (1979) (0)
Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome. (2008) (0)
Prevention of chemotherapy-induced leukemia and of leukemia relapses (1991) (0)
The Clinical Pharmacology of New Agents related to the Treatment of Diffuse Meningeal Carcinomatosis (1979) (0)
Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy (2008) (0)
Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology. (2016) (0)
Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes. (2004) (0)
THE FUNCTION AND FATE O F TRANSFUSED LEUKOCYTES IN LEUKOPENIC RECIPIENTS FROM DONORS WlTH CHRONIC MYELOCYTIC LEUKEMIA (2006) (0)
Triumphs and challenges in oncology (2001) (0)
Leukemia research, 2008. (2009) (0)
Randomized Phase II Study of Fludarabine 1 Cytosine Arabinoside 1 Idarubicin 6 All-Trans Retinoic Acid 6 Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome (1999) (0)
malignant lymphoma Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) (2011) (0)
Overall Survival in Hematopoietic Stem Cell Transplantation Is Not Correlated with Age of Red Cells Transfused Pre- and Post-Transplantation (2014) (0)
Commentary on Thomas and Epstein: "Bone Marrow Transplantation in Acute Leukemia". (2016) (0)
Combination therapy with arsenic trioxide (ATO), all-trans retinoic acid (ATRA), and gemtuzumab ozogamycin (GO) in relapsed acute promyelocytic leukemia (APL). (2006) (0)
Proceedings: Management of acute leukemia. (1972) (0)
510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation (2011) (0)
Results o f T reatment W ith H yper-CVAD, a D ose-Intensive Regimen, i n A dult A cute L ymphocytic L eukemia (2000) (0)
Patterns of Failure in Salvage Therapy for Acute Myelogenous Leukemia (1992) (0)
Summary of the Conference (1987) (0)
Editorial: Approaches to local immunotherapy. (1975) (0)
R 4 S Mutations Are Rare Events in Philadelphia Chromosome-Negativelbcr Gene Rearrangement-Negative Chronic Myelogenous Leukemia , But Are Prevalent in Chronic Myelomonocytic Leukemia (2003) (0)
New approaches to the treatment of chronic myelogenous leukemia. (1985) (0)
Erythroid homograft following transfusion in a patient with acute leukemia (1966) (0)
In memoriam Benjamin Drewinko, M.D., Ph.D (1940-1987). (1987) (0)
Cytapheresis and plasma exchange: clinical indications. Conference summary and future directions. (1982) (0)
The Lymphatics in Cancer. (1974) (0)
Therapy of acute myelogeneous leukemia. (1978) (0)
Mechanism of action of ZIO-101 (S-dimethylarsino-glutathione), an organic arsenic derivative that is equally effective and less toxic than arsenic trioxide (2004) (0)
Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML) (2007) (0)
Process for ethylene recovery low pressure (1971) (0)
Folic Acid Antagonists (2020) (0)
The role of molecular genetics in medical oncology (1994) (0)
Factors influencing patient selection for chemotherapy studies of acute leukemia. (1962) (0)
Chapter 03: Perfecting the Blood Separator in the Department of Developmental Therapeutics: Shifting MD Anderson Culture to Innovative Research (2011) (0)
The proceedings of the initial meeting of the Society of Hematologic Oncology 2013. (2014) (0)
In Vitro Evaluation of l-ÃŸ-D-Arabinofuranosylcytosine-ÃŸ-2'-DeoxythioguanosineCombination Chemotherapy1 (2006) (0)
Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors (1989) (0)
The effect of anti cancer drugs on the labelling index of human solid tumours in vitro: preliminary correlation with clinical response (1976) (0)
Conception and Pregnancy in Patients (pts) with Chronic Myeloid Leukemia (CML) Receiving Therapy with Imatinib Mesylate (IM). (2005) (0)
Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections (2018) (0)
An Overview of Adjuvant Therapy in Man (1980) (0)
Detection of minimal residual disease in acute myeloblastic leukemia. (1994) (0)
Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014 (2015) (0)
Different Patterns of Remisson in Acute Myelocytic Leukemia (1963) (0)
Rethinking the randomized clinical trial: the 21st century application of Freireich's laws. [An interview with Emil J Freireich by H&O]. (2008) (0)
Splenectomy in chronic myelogenous leukemia (CML) patients: A long term follow up (1979) (0)
Prognostic factors in response to anthracyclines. (1981) (0)
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). (2001) (0)
Resul ts of Treatment With Hyper-CVAD , a Dose-Intens ive Regimen , in Adul t Acute Lymphocyt ic Leukemia (2000) (0)
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center (2011) (0)
groups of adult acute lymphoblastic leukemia therapy for central nervous system prophylaxis in different risk The value of high-dose systemic chemotherapy and intrathecal (2011) (0)
In Vitro Determination of Thy midlne-3 H Labeling Index in Human Solid Tumors1 (2006) (0)
Supportive care for patients with blood disorders (2000) (0)
Our hematologic heritage. (1991) (0)
Clinical research today and tomorrow. (2001) (0)
Modulation of 9-/?-r>Arabinofuranosyladenme S'-Triphosphate and Deoxyadenosine Triphosphate in Leukemic Cells by 2'-Deoxycoformycin during Therapy with 9-ÃŸ-o-Arabinofuranosyladenine1 (2006) (0)
Treatment of Colorectal Cancer-Reply (1976) (0)
Masked Translocation in Acute Myelogenous Leukemia (2007) (0)
In vitro evaluation of ara C, β TGdR combination chemotherapy (1974) (0)
The impact of cytogenetics and molecular genetics on the treatment of leukemia. (1990) (0)
The Impact of Treatment on the Natural History of Acute Leukemia (1985) (0)
V. Summary (1961) (0)
Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients. (2006) (0)
Leukemia: 6-Mercaptopurine and Methotrexate Studies of Sequential and Combination Antimetabolite Therapy in Acute (2013) (0)
Preventing Platelet Alloimmunization for Patients with Hematologic Malignancies: Rapid HLA-class I and HPA Immunogenetic Profiling to Enable Selection of Optimally Matched Platelets (2012) (0)
Retrospect of hematologic malignancies 2010. (2011) (0)
Progress in Clinical Cancer, vol 5. (1974) (0)
Comparison of Two Apheresis Instruments (Old vs. New) for Granulocyte Collection: A Single Institutional Experience (2016) (0)
Refractory" Acute Leukemia. Studies of 6-Azauracil Evaluation of a New Chemotherapeutic Agent in Patients with "Advanced (2011) (0)
Survival curves, prognostic factors and continuous medical record analysis in acute leukemia. (1976) (0)
Overall survival in hematopoietic stem cell transplantation is correlated with the Number butnotwith the Age of Red Blood Cells Transfused (2017) (0)
Reduction of Ifosfamide Toxicity Using Dose Fractionation1 (2006) (0)
Approaches to Local Immunotherapy (1975) (0)
The impact of molecular genetics on the detection of residual malignant disease (1991) (0)
Development of promyelocyte lines from the bone marrow of patients with acute myeloid leukemia in rIL2 (1993) (0)
Chronic myelocytic leukemia [2] (1993) (0)
Hematologic malignancies: A personal perspective (1989) (0)
syndromes Angiogenesis in acute and chronic leukemias and myelodysplastic (2013) (0)
Chronic Lymphocytic Leukemic Lymphocytes Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant (2010) (0)
Medical Management of Hematologic Malignant Diseases (1998) (0)
OP01 Treatment of acute leukemia: 50 years later (2007) (0)
Research contributions to supportive measures for cancer chemotherapy. (1972) (0)
Chapter 17: The Beginning of the Division System, Closing Developmental Therapeutics (1983), and the Legacy of the Department (2001) (0)
Foundations of clinical cancer research : perspective for the 21st century : a symposium to honor Emil J. Freireich, M.D., on the occasion of his 70th birthday, M.D. Anderson Cancer Center, Huston, TX, March 14-15, 1997 (1997) (0)
Untreated Patients with Acute Myeloid Leukemia, Age 50–59 Years and Performance Status 2 Should Be as Eligible for Targeted Therapy as Older Patients. (2007) (0)
Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196). (1975) (0)
Flow Cytometry in Clinical Cancer Research 1 (2006) (0)
Chairman's summary (1980) (0)
Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy (2017) (0)
Does transfusion of aged red blood cells lead to adverse outcomes in Acute Myeloid Leukemia patients undergoing Hematopoietic stem cell Transplantation (2015) (0)
THE CONTROL OF ACUTE LEUKEMIA. (1965) (0)
Future trends in apheresis. (1981) (0)
Randomized Phase II Study of Fludarabine1 Cytosine Arabinoside1 Idarubicin 6 All-Trans Retinoic Acid 6 Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome (1999) (0)
Butterworths international medical reviews — Hematology 1 — Leukemias: edited by John M. Goldman and Harvey D. Preisler (Butterworths, 1984) (1985) (0)
Vinca alkaloids. (1989) (0)
Interferon alfa-2b plus low dose cytarabine for the maintenance of remission in acute myeloid leukemia and advanced myelodysplastic syndrome (2000) (0)
Exclusion from Acute Myeloid Leukemia (AML) Clinical Trials of Patients Unlikely To Respond. (2007) (0)
The Society of Hematologic Oncology (SOHO): moving forward in the battle against hematologic malignancies. (2012) (0)
Millennium review Angiogenesis and leukemia (2001) (0)
Introduction to E. Donnall Thomas (1997) (0)
Invited remarks (1979) (0)
Book Review: Therapeutic Revolution - The History of Medical Oncology from Early Days to the Creation of the Subspecialty (2015) (0)
α chromosome-positive chronic myeloid leukemia after failure of interferon- Result of high-dose imatinib mesylate in patients with Philadelphia (2013) (0)
Acute leukaemia in adults: 1977 (1977) (0)
Lesson on leukemia. (2002) (0)
92 Safety and efficacy of recombinant interferon-gamma-1b (rIFN-γ1b) immune adjuvant in 20 patients receiving high-dose donor granulocyte transfusions (GTX): An observational study during 2000–2004 (2006) (0)
Blood component collection and transfusion. (1979) (0)
in thronic Long-Term Results of CAP Therapy Lymphocytic Leukemia (1990) (0)
Program Genealogies: A History of Leukemia Research at MD Anderson Cancer Center (1965-Present) (2017) (0)
Retrospect of hematological malignancies 2012. (2013) (0)
The use of clinical data to predict response to therapy. (1988) (0)
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer (1997) (0)
A symposium on cancer chemotherapy. IV. Acute leukemia. (1962) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Emil. J. Freireich?

Emil. J. Freireich is affiliated with the following schools:

MD Anderson Cancer Center